key: cord-0994123-ag46oqf3
authors: Kornowski, Ran
title: Shifting Paradigms in Cardiovascular Therapeutic Strategies During the COVID-19 Era
date: 2020-05-19
journal: JACC Cardiovasc Interv
DOI: 10.1016/j.jcin.2020.05.028
sha: 5d14c45a79089f31615ce950d46a2948cd80b6f8
doc_id: 994123
cord_uid: ag46oqf3

The coronavirus disease-19 (COVID-19) period have dictated a different approach to cardiac interventions at our medical institution. We prioritize emergent care geared toward lesser invasive approaches while minimizing hospitalization duration. This reflects upon coronary and structural/valvular cases altogether. Despite potential criticism of this approach, we believe it is the most appropriate therapeutic strategy for this unique period. Further investigation is needed to examine the external validity of our approach in other medical centers worldwide.

Last week, I treated a patient who was admitted to our Cardiology Department with unstable angina. He was an active 65-year-old man with diabetes mellitus, obesity, hypertension, and dyslipidemia, and his coronary angiogram showed triple vessel coronary artery disease with tight lesions in the left anterior descending, left circumflex, and right coronary arteries. The culprit lesion was in the left anterior descending artery and his Syntax score (signifying the overall coronary measure of severity and complexity) was 22. According to the contemporary revascularization guidelines adopted in most countries (1, 2) , I should have stopped the procedure, discussed it with our cardiac surgical colleagues, and potentially offered the patient coronary bypass surgery as the default revascularization strategy. This recommendation is based on several studies indicating a prognostic cardiovascular benefit over time for coronary bypass grafting (CABG) surgery versus catheter-based revascularization in diabetic patients with multivessel disease (3). The "heart team" paradigm has been promoted over the last decade, despite no study being able to show its inevitability (4), but the concept has gained popularity in multiple centers across the globe based on strong advocacy in the ESC/ACC/AHA guidelines (1, 2, 5, 6) .

Confronted with my patient's status amidst COVID-19, I thought to myself that the pre-COVID-19 paradigm concerning revascularization strategies is no longer valid, at least during the "stormy" present. Therefore, I performed a multi-vessel percutaneous coronary intervention (PCI) using the radial approach and, after 40 minutes, the patient's three vessels were opened effectively using four thin-strut drug-eluting stents without any complications. The patient did well and was discharged early the next morning with recommendations for changing his lifestyle and using evidence-based medications to prevent repeat cardiovascular events, adjusted for his diabetic status. In this case, no heart team was involved in pursuing the percutaneous approach, which is remarkable due to the impact of the COVID-19 outbreak on our medical center. This is a period that has dictated multiple rapid changes in our medical practices. For cardiovascular interventions, we adopted a policy of swift and highly focused work-up and therapeutic strategies, which also means a dramatic change in the way we treat our cardiac patients, According to this approach, over the last 2 months we have maximized our PCI practice of complex coronary interventions, including unprotected left mains and multivessel revascularizations, resulting in a 67% decrease in CABG referrals despite only 16% decrease in our PCI volume. We also increased our TAVR volume to encompass low-and certainly intermediate/high-risk patients, with 22 cases during March 2020 compared to our usual monthly volume of approximately 16 procedures (37.5% increase). We also performed four MitraClip procedures, whereas our average volume is two per month. We felt that our patients received the appropriate and necessary treatment, though adjusted for this particular time. Nevertheless, the patients were "part of the equation", and we were transparent by telling them that, under regular circumstances, we may have offered a different treatment. All of the patients, without exception, were delighted with our approach and approved our strategy. "Just do what you need to do" and "get me out of the hospital as fast as you can" were the most common messages from our patients.

One may criticize our adaptive approach. I would presume that cardiac surgeons, or even some cardiologists, may refute our strategy, and I fully respect their view. The counterarguments are based on the need to optimize cardiovascular care under any circumstances while taking into account the long-term prognosis rather than having short-term solutions that may jeopardize the patient's health and well-being in the long run. In addition, the concept of the heart team forum was meant to optimize cardiac care at large; thus, "excluding" the surgeons from the decisionmaking process in many circumstances may be perceived as misconduct, which certainly does not align with the recommended cardiology practice guidelines; therefore, this path should not be pursued.

I fully respect those who may criticize what we do, but I think that, during this particularly challenging period, I can stand behind our therapeutic decisions. I believe it is crucial to provide ad hoc and high-quality treatments for our cardiac patients while setting medical priorities that meet the patients' expectations. In the COVID-19 era, patients want highquality, expedited treatment while minimizing their stay in the hospital. It is already difficult to convince patients to be admitted, and we have seen multiple life-threatening delays in cardiac presentations and/or interventions, including among patients with acute myocardial infarction.

In summary, the COVID-19 period dictates a different approach to cardiac interventions at our medical institution. We prioritize emergent care geared towards lesser invasive approaches while minimizing hospitalization. Despite potential criticism of this approach, we believe it is the most appropriate therapeutic strategy in our hospital environment. As we continue to monitor all of our patients at outpatient clinics or via tele-medicine and conduct a comprehensive detailed follow-up of our cardiac interventions, we intend to validate this strategy in order to ensure that it is indeed appropriate and safe. Further research is needed to examine the external validity of our approach in other medical centers and medical institutions worldwide.

ESC/EACTS Guidelines on myocardial revascularization

ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data

The pros and cons of the Heart Team

ESC/EACTS Guidelines for the management of valvular heart disease

AHA/ACC Focused Update of the

Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines